<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477150</url>
  </required_header>
  <id_info>
    <org_study_id>NTWC/CREC/15029</org_study_id>
    <nct_id>NCT02477150</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Zoster Vaccine in SLE</brief_title>
  <official_title>Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tuen Mun Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tuen Mun Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the safety and immunogenicity of a herpes zoster vaccine in patients with SLE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Herpes zoster (HZ) (Shingles) is a painful condition caused by reactivation of varicella&#xD;
      zoster virus (VZV) that remains dormant after primary infection. HZ reactivation may cause&#xD;
      significant morbidity such as post-herpetic neuralgia and even mortality for disseminated&#xD;
      infection, particularly in immunocompromised individuals.&#xD;
&#xD;
      HZ vaccine (Zostavax) is essentially a larger-than-normal dose of the chickenpox vaccine,&#xD;
      which contains the Oka strain of live attenuated VZV. Zostavax has been shown to be safe and&#xD;
      protective in immunocompetent elderly populations (&gt;60 years of age) by reducing reactivation&#xD;
      of HZ by 51% and post-herpetic neuralgia by 66%. Another study also demonstrated efficacy of&#xD;
      Zostavax in reducing HZ infection by 70% in adults aged 50-59 years.&#xD;
&#xD;
      Data regarding the use of HZ vaccine in patients with rheumatic diseases are scant. A recent&#xD;
      observational study involving 463,541 US patients with rheumatoid arthritis, inflammatory&#xD;
      bowel disease, psoriatic arthritis and ankylosing spondylitis showed that 4% of patients had&#xD;
      received HZ vaccination. After a median observation period of 2 years, the rate HZ&#xD;
      reactivation among vaccinated patients was significantly lower than that of unvaccinated&#xD;
      group (hazard ratio 0.61 [0.52-0.71]). Among 633 patients exposed to biologics at the time of&#xD;
      vaccination, no cases of HZ or varicella infection occurred in the subsequent 42 days after&#xD;
      vaccination. Thus, the vaccine appears to be safe in patients with autoimmune rheumatic&#xD;
      diseases even receiving the biological agents.&#xD;
&#xD;
      HZ reactivation is fairly common in patients with systemic lupus erythematosus (SLE).&#xD;
&#xD;
      However, data regarding HZ vaccination in SLE patients are generally lacking. Safety and&#xD;
      efficacy of HZ vaccination has recently been demonstrated in other immunocompromised groups&#xD;
      such as HIV infection, post-chemotherapy and hematological malignancies. According to the&#xD;
      2011 EULAR recommendation, HZ vaccination may be considered in patients with autoimmune&#xD;
      inflammatory rheumatic diseases provided that they are less seriously immunosuppressed.&#xD;
&#xD;
      The current study is designed to test for the immunogenicity and safety of a HZ vaccine&#xD;
      (Zostavax) in patients with stable SLE who are receiving minimal immunosuppressive therapies&#xD;
      for maintenance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>antibody rise to varicella zoster virus</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference between the two groups in the proportion of patients who achieve a two-fold rise in IgG to VZV at week 6 post-vaccination compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety (incidence of herpes zoster reactivation or chickenpox infection)</measure>
    <time_frame>week 6</time_frame>
    <description>incidence of herpes zoster reactivation or chickenpox infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell response to VZV</measure>
    <time_frame>week 6</time_frame>
    <description>differences between IFN release upon VZV stimulation of PBMC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>SLE (vaccine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zostavax SC injection (0.65ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLE (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC injection (normal saline 0.65ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zostavax</intervention_name>
    <description>Vaccination of a zoster vaccine (Zostavax)</description>
    <arm_group_label>SLE (vaccine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo administration</description>
    <arm_group_label>SLE (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. SLE patients who fulfill ≥4 of the 1997 ACR (17) or the 2012 SLICC/ACR criteria for&#xD;
             SLE (18)&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Clinically inactive disease with SELENA-SLEDAI score &lt;6 (see below) and receiving&#xD;
             stable dose of immunosuppressive agents for ≥6 months&#xD;
&#xD;
          4. History of varicella (chickenpox) or herpes zoster infection in the past&#xD;
&#xD;
          5. Willing to comply with all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active infection, including upper respiratory tract infection&#xD;
&#xD;
          2. Active untreated tuberculosis&#xD;
&#xD;
          3. Human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          4. Lymphocyte count &lt;500/mm2&#xD;
&#xD;
          5. Reduced serum IgG, IgA or IgM level (below normal range)&#xD;
&#xD;
          6. Serum creatinine &gt;200umol/L&#xD;
&#xD;
          7. History of hematological malignancies (eg. lymphoma, leukaemia) and other solid tumors&#xD;
&#xD;
          8. Patients receiving doses of immunosuppressive agents exceeding the following:&#xD;
&#xD;
               -  Prednisolone (&gt;15mg) or equivalent&#xD;
&#xD;
               -  Azathioprine (&gt;100mg/day)&#xD;
&#xD;
               -  Mycophenolate mofetil (&gt;1000mg/day)&#xD;
&#xD;
               -  Cyclosporin A (&gt;100mg/day)&#xD;
&#xD;
               -  Tacrolimus (&gt;3mg/day)&#xD;
&#xD;
               -  Methotrextate (&gt;15mg/week)&#xD;
&#xD;
               -  Cyclophosphamide (any dose)&#xD;
&#xD;
               -  Biological agents eg. rituximab, belimumab (any dose)&#xD;
&#xD;
          9. Patients who are pregnant or plan to become pregnancy within one year of study entry&#xD;
&#xD;
         10. Patients who cannot give a written consent (mentally incapable or illiterate)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CC Mok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tuen Mun Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2015</study_first_posted>
  <last_update_submitted>September 2, 2019</last_update_submitted>
  <last_update_submitted_qc>September 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tuen Mun Hospital</investigator_affiliation>
    <investigator_full_name>Chi Chiu Mok</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

